Myeloma

Cancer (3199)
Cervical cancer (22)
Myeloma (20)

Synopsis: Health: Illness: Cancer, neoplasms and tumors: Cancer: Myeloma:

All patients diagnosed with myeloma, a cancer of the blood-producing bone marrow, first develop a relatively benign condition called'monoclonal gammopathy of undetermined significance'or MGUS."

"Our findings show that very few changes are required for a MGUS patient to progress to myeloma as we now know virtually all patients with myeloma evolve from MGUS,

"A drug that interferes with these initial metabolic changes could make very effective treatment for myeloma,

However, currently there is no way of accurately predicting which patients with MGUS are likely to go on to get myeloma.

and blood samples taken from patients with myeloma, patients with MGUS and healthy volunteers. Surprisingly, the researchers found that the metabolic activity of the bone marrow of patients with MGUS was significantly different to plasma from healthy volunteers,

but there were very few differences at all between the MGUS and myeloma samples. The research team found over 200 products of metabolism differed between the healthy volunteers

and patients with MGUS or myeloma, compared to just 26 differences between MGUS patients and myeloma patients.

The findings suggest that the biggest metabolic changes occur with the development of the symptomless condition MGUS and not with the later progression to myeloma.

The researchers believe that these small changes could drive the key shifts in the bone marrow required to support myeloma growth.

the Winthrop P. Rockefeller Cancer Institute, the Jackson T. Stephens Spine & Neurosciences Institute, the Myeloma Institute, the Harvey & Bernice Jones Eye Institute, the Psychiatric Research

In a paper published today in the journal Cancer cell the researchers report how the drug known as DTP3 kills myeloma cells in laboratory tests in human cells

-B pathway with our DTP3 peptide therapeutic selectively kills myeloma cells could offer a completely new approach to treating patients with certain cancers such as multiple myeloma Professor Franzoso said.

where myeloma tumors typically are showed found, and a long-term ability to fight the tumors. Relapse was associated generally with a loss of the engineered T-cells. his study suggests that treatment with engineered T-cells is not only safe

. the Gary Jobson Professor in Medical Oncology at the University of Maryland School of medicine. ur findings provide a strong foundation for further research in the field of cellular immunotherapy for myeloma to help achieve even better

and LAGE-1. Up to 60 percent of advanced myelomas have been reported to express NY-ESO-1 and/or LAGE-1,

and Dr. Rapoport, who have been research collaborators for 18 years. ultiple myeloma is a treatable but largely incurable cancer.

or cancerous, plasma cells, myeloma is treatable but incurable. he median survival rate has improved, but is only about five to seven years,

which is used often to treat myeloma, and it only took them three days to see

< Back - Next >

Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011